- Home
- EVAX vs ADXN Comparison
EVAX vs ADXN Comparison
Compare EVAX & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- ADXN
- Stock Information
- Founded
- EVAX 2008
- ADXN 2002
- Country
- EVAX Denmark
- ADXN Switzerland
- Employees
- EVAX N/A
- ADXN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- ADXN Health Care
- Exchange
- EVAX Nasdaq
- ADXN Nasdaq
- Market Cap
- EVAX 15.1M
- ADXN 10.1M
- IPO Year
- EVAX 2021
- ADXN N/A
- Fundamental
- Price
- EVAX $2.67
- ADXN $9.00
- Analyst Decision
- EVAX Strong Buy
- ADXN Strong Buy
- Analyst Count
- EVAX 2
- ADXN 1
- Target Price
- EVAX $10.00
- ADXN $30.00
- AVG Volume (30 Days)
- EVAX 104.8K
- ADXN 14.4K
- Earning Date
- EVAX 08-13-2025
- ADXN 08-11-2025
- Dividend Yield
- EVAX N/A
- ADXN N/A
- EPS Growth
- EVAX N/A
- ADXN N/A
- EPS
- EVAX N/A
- ADXN 0.10
- Revenue
- EVAX $3,293,000.00
- ADXN $278,508.00
- Revenue This Year
- EVAX N/A
- ADXN $86.57
- Revenue Next Year
- EVAX N/A
- ADXN N/A
- P/E Ratio
- EVAX N/A
- ADXN $0.78
- Revenue Growth
- EVAX 2555.64
- ADXN N/A
- 52 Week Low
- EVAX $1.20
- ADXN $6.51
- 52 Week High
- EVAX $17.75
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- EVAX 58.34
- ADXN 49.41
- Support Level
- EVAX $2.26
- ADXN $8.78
- Resistance Level
- EVAX $2.85
- ADXN $9.89
- Average True Range (ATR)
- EVAX 0.22
- ADXN 0.67
- MACD
- EVAX 0.00
- ADXN -0.03
- Stochastic Oscillator
- EVAX 59.54
- ADXN 43.01
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.